The global DNA diagnostics market size was estimated at USD 10.69 billion in 2023 and is projected to hit around USD 16.05 billion by 2033, growing at a CAGR of 4.15% during the forecast period from 2024 to 2033 according to a new report by Nova One Advisor.
The global DNA diagnostics market size was estimated at USD 10.69 billion in 2023 and is projected to hit around USD 16.05 billion by 2033, growing at a CAGR of 4.15% during the forecast period from 2024 to 2033 according to a new report by Nova One Advisor.
Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/8459
The growth of the market is attributed to an increase in the incidence of genetic, infectious, and chronic diseases as well as decreasing prices of genetic sequencing technologies aided by the growing adoption of precision medicine diagnostic techniques. The market is primarily driven by DNA profiling, which aims to enhance the understanding of disease predisposition and potential adverse reactions associated with existing or under-clinical development drugs. The increasing significance of early diagnosis and prevention, alongside the growing demand for DNA tests in areas such as pharmacogenomics and cancer genetic testing, contributes significantly to market growth.
The growing demand for DNA diagnostics is expected to be driven by various factors. One such factor is the increasing implementation of personalized medicine applications for the treatment of chronic disorders. This approach emphasizes tailoring medical interventions based on an individual’s genetic profile, leading to a growing need for HLA typing and DNA identification for therapy. Furthermore, the demand for DNA diagnostics is expected to be fueled by advancements in technology that enable the commercialization of next-generation diagnostic and testing solutions utilizing genetic analysis. These hi-tech advancements offer more advanced and precise tools for genetic analysis, contributing to improved diagnostic accuracy and expanded testing capabilities. Thus, collectively, these factors are anticipated to increase growth.
With the rising demand for newborn and pre-natal screening aimed at detecting congenital abnormalities, an increased focus on early detection and intervention drives the need for DNA testing in these screening programs. Furthermore, the application of DNA testing as a crucial step in biobanking services, particularly in cord blood banking, contributes to sector growth. Physicians’ higher inclination towards genetic testing to determine patients’ health at different stages of disease development is another factor expected to fuel demand in the coming years.
However, one of the major factors hampering the market’s growth is the high cost associated with the development of these diagnostic tests. The research and development (R&D) efforts related to introducing new techniques and implementing them in practice are expensive and have a high cost associated with them. These costs can be a barrier for some companies and hinder overall industry growth.
Moreover, stringent government regulations surrounding DNA prototyping and the need for a clear reimbursement structure are anticipated to pose obstacles for new market entrants. Compliance with these regulations and navigating the reimbursement landscape can be complex and time-consuming, discouraging potential players from entering the market. Overall, while the market for DNA diagnostics exhibits significant potential, these challenges need to be addressed to ensure sustained growth and a favorable environment for innovation and competition.
Key Takeaways:
- North America dominated the DNA diagnostics market in 2023 with a revenue share of 43.45%.
- Asia Pacific is expected to witness the fastest CAGR of 6.24% from 2024 to 2033
- In terms of technology, the PCR-based diagnostics segment held the largest revenue share of 52.03% in 2023.
- Next-generation sequencing (NGS)-based diagnosis is anticipated to witness the fastest CAGR of 7.98% over the forecast period
- Based on application, cancer genetics tests dominated the market in 2023 with a revenue share of 30.58% in 2023.
- Infectious diseases DNA testing is anticipated to grow at the fastest CAGR of 4.51% over the forecast period.
DNA Diagnostics Market Top Trends?
DNA diagnostics are increasingly being used to tailor medical treatments to individual patients based on their genetic makeup. This trend is expected to continue as technology advances and costs decrease.
- Direct-to-Consumer Testing:
With the availability of affordable DNA testing kits, more consumers are opting to directly access genetic information about their ancestry, health risks, and traits. This trend is driving growth in the direct-to-consumer DNA testing market.
- Rapid Advancements in Technology:
Technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) continue to evolve, enabling faster, more accurate, and cost-effective DNA analysis. These advancements are expanding the applications of DNA diagnostics.
- Expanded Clinical Applications:
DNA diagnostics are increasingly being used in various clinical settings beyond traditional genetic testing, including oncology, infectious diseases, pharmacogenomics, and prenatal screening. This expansion of applications is driving market growth.
- Integration of Artificial Intelligence (AI) and Big Data:
AI and big data analytics are being integrated into DNA diagnostics platforms to improve data interpretation, identify patterns, and enhance diagnostic accuracy. This trend is expected to streamline workflows and improve patient outcomes.
- Growing Demand for Non-Invasive Testing:
Non-invasive DNA testing methods, such as liquid biopsy for cancer detection and prenatal testing through maternal blood samples, are gaining popularity due to their convenience and reduced risk to patients. This trend is expected to continue as these technologies become more sophisticated and accessible.
- Regulatory Landscape:
Regulatory agencies are increasingly focusing on the oversight of DNA diagnostics to ensure accuracy, reliability, and ethical use of genetic information. Compliance with regulations and guidelines is becoming increasingly important for companies operating in this market.
Immediate Delivery Available, Get Full Access@
https://www.novaoneadvisor.com/report/checkout/8459
Technology Insights
In terms of technology, the PCR-based diagnostics segment held the largest revenue share of 52.03% in 2023. The dominance of the segment is attributed to the widespread market usage and high availability of products owing to the presence of a significant number of players offering PCR-based diagnostics in the market. Moreover, PCR offers high sensitivity and specificity, allowing for the detection of even small amounts of DNA in a sample. This makes it particularly useful in diagnosing infectious diseases and genetic disorders and identifying genetic variations associated with cancer and other diseases. In May 2023, Sensible Diagnostics, a Los Angeles-based organization, announced that they are targeting the introduction of a 10-minute point-of-care PCR system by early next year. Thus, these factors are anticipated to bolster the growth of PCR-based diagnostic technology, thereby fueling the market growth.
Next-generation sequencing (NGS)-based diagnosis is anticipated to witness the fastest CAGR of 7.98% over the forecast period owing to the development of innovative and breakthrough advancements in the market. NGS platforms have the ability to process multiple samples in parallel, allowing for high-throughput sequencing. This increased efficiency makes NGS suitable for applications such as whole-genome sequencing, exome sequencing, targeted gene panels, and transcriptome analysis. Moreover, NGS-based Diagnostics play a crucial role in advancing precision medicine approaches. By providing detailed genetic information, NGS enables personalized treatment decisions, prognostic assessments, and the identification of targeted therapies based on an individual’s genomic profile. Thus, the availability of various platforms for sequencing and analysis of DNA data that result in efficient, highly accurate, and rapid diagnosis is further expected to fuel the growth of the segment.
Application Insights
Based on application, cancer genetics tests dominated the market in 2023 with a revenue share of 30.58% in 2023. The dominance of the segment can be attributed to the growing prevalence of cancer globally, increased adoption of personalized medicine, and growing technological advancements in DNA sequencing technology. The development of advanced DNA sequencing technologies, such as NGS, has made cancer genetic testing more accessible, efficient, and cost-effective. These technologies allow for comprehensive analysis of multiple genes simultaneously, increasing the accuracy and efficiency of genetic testing for cancer.
Certain genetic mutations are known to be strongly associated with hereditary cancer syndromes, such as BRCA1 and BRCA2 mutations in breast and ovarian cancer. Cancer genetics tests can identify these mutations, enabling proactive screening and preventive measures for individuals with a higher genetic predisposition to cancer. Thus, these factors are anticipated to boost the cancer genetics tests application, thereby fueling the DNA diagnostic market over the forecast period.
Infectious diseases DNA testing is anticipated to grow at the fastest CAGR of 4.51% over the forecast period. DNA testing methods have proven to be highly important in infectious disease diagnosis and clinical confirmation. This application segment has generated substantial revenue due to the availability of various products designed for diseases such as HBV, HCV, HIV, TB, CT/NG, HPV, and MRSA. In addition, the increasing utilization of DNA diagnostics in chronic oncology cases and related abnormalities is expected to drive significant growth in the oncology diagnostics & histopathology segment in the near future. The adoption of sequencing technology for tumor detection and biomarker analysis is another factor contributing to the overall market growth throughout the forecast period.
Regional Insights
North America dominated the DNA diagnostics market in 2023 with a revenue share of 43.45%. The presence of sophisticated healthcare infrastructure, strong government initiatives, proactive funding for DNA testing research, and the high prevalence of chronic diseases are the major drivers for market growth in this region. Furthermore, North America has seen widespread adoption of genetic testing for various purposes, such as disease risk assessment, pharmacogenomics, prenatal screening, and ancestry testing. The availability of advanced laboratory facilities, favorable reimbursement policies, and a large population base with access to healthcare contribute to the region’s dominance in the DNA diagnostic market.
Asia Pacific is expected to witness the fastest CAGR of 6.24% from 2024 to 2033 due to rising research & development incentives offered by the government in developing economies such as China and India, which enable R&D and commercialization of technologically innovative products. Moreover, the high accessibility of the target population owing to the prevalence of chronic diseases is also anticipated to supplement growth in the coming years. In addition, the region has witnessed significant advancements in DNA sequencing technologies, such as NGS. These technological developments have made DNA diagnostics more accessible, efficient, and cost-effective, thereby driving market growth.
Key Companies & Market Share Insights
Market participants are involved in R&D for the introduction of rapid testing methods that provide reproducible and accurate results and aid in the diagnosis of genetic abnormalities. For instance, in April 2023, Agilent Technologies Inc. announced the launch of SureSelect Cancer CGP Assay, which is particularly devised for somatic variant profiling for a broad wide range of solid tumor forms. Furthermore, these entities are also engaged in developing and updating their databases for mining and comparing DNA specimens to help law enforcement in solving criminal cases. Some prominent players in the global DNA diagnostics market include:
- GE Healthcare
- Abbott
- Beckman Coulter Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Cepheid.
- Hologic, Inc.
- Siemens HealthcareGmbH
- F. Hoffmann-La Roche
- QIAGEN
- Agilent Technologies Inc.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the DNA Diagnostics market.
By Technology
- Microarrays-based Diagnostics
- PCR-based Diagnostics
- In-situ Hybridization Diagnostics
- NGS DNA Diagnosis
By Application
- Cancer Genetics Tests
- Infectious Diseases DNA Testing
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Newborn Genetic Screening
- Preimplantation & Reproductive Diagnosis
- Non-Infectious Diseases DNA Testing
- Cardiovascular Diseases
- CNS & PNS Related
- Skeletal, Connective, Ectodermal & Dermal DNA Testing
- Lung, Kidney, Liver & GT Related
- Sensory Diseases
- Prenatal DNA Carrier Screening
- Pharmacogenomics/Drug Metabolism
- Hematology & Immunology/Identity Diagnostics & Forensics
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Order the 150+ Pages Detailed Report @ https://www.novaoneadvisor.com/report/checkout/8459
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: sales@novaoneadvisor.com
